.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent chemical research has successfully achieved the total synthesis of (-)-garvensintriol, a potent cytotoxic styryllactone derived from the plant Goniothalamus arvensis. During this process, scientists identified significant errors in the previously proposed chemical structure. This Garvensintriol structural revision clarifies the stereochemistry at the C-5 and C-6 positions, providing a more accurate understanding of the molecule's properties.
Moreover, the study demonstrates that the compound is actually a five-membered γ-butyrolactone. Previously, experts had classified it as a saturated δ-lactone. Consequently, this correction ensures that future pharmacological studies rely on the accurate molecular blueprint. Researchers utilized meticulous synthetic efforts, single-crystal X-ray diffraction, and Density Functional Theory (DFT) calculations to confirm these findings.
The Garvensintriol structural revision is not merely a chemical technicality. In addition to the structural update, the study suggests that (+)-garvensintriol and (-)-3-deoxycardiobutanolide are identical natural products. This finding simplifies the chemical landscape for styryllactones, which are widely recognized for their cytotoxic properties against various cancer cell lines. Therefore, oncology researchers can now better understand the structure-activity relationships of these molecules.
Furthermore, the unambiguous confirmation through total synthesis provides a reliable route for producing this compound in laboratory settings. Such access is crucial for conducting more extensive in vitro and in vivo studies. Understanding the Garvensintriol structural revision helps medicinal chemists design more effective analogs with potentially lower toxicity and higher efficacy for cancer treatment.
The revision ensures that oncology research and drug development targeting cytotoxic styryllactones are based on the correct molecular structure, preventing errors in synthesis and pharmacological modeling.
Yes, research indicates that the revised structure of garvensintriol is identical to (-)-3-deoxycardiobutanolide, confirming they are the same substance despite previous nomenclature differences.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Zhang Y et al. Total Synthesis and Structural Revision of (-)-Garvensintriol. J Nat Prod. 2026 Jun 03. doi: 10.1021/acs.jnatprod.6c00456. PMID: 42233247.
2. Lu Z et al. Styryllactones from the genus Goniothalamus: A review of their chemistry and biological activities. Phytochemistry. 2020;178:112464.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers have revised the structure of (-)-Garvensintriol, a cytotoxic styryllactone, confirming it is identical to (-)-3-deoxycardiobutanolide....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
